热门资讯> 正文
Maze Therapeutics GAAP每股收益为-18.32美元
2025-04-01 01:28
- Maze Therapeutics press release (NASDAQ:MAZE): Q4 GAAP EPS of -$18.32.
- Cash and cash equivalents were $196.8 million as of December 31, 2024, compared to $29.2 million as of December 31, 2023.
- Maze expects its current cash and cash equivalents, which includes proceeds from its February 2025 IPO, will fund operations into the second half of 2027.
More on Maze Therapeutics
- Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist
- Maze Therapeutics Seeks IPO For Trials Ramp-Up
- Maze Therapeutics stock hugs flat line following $140M IPO
- Kidney disease drug developer Maze files for $100M IPO
- Historical earnings data for Maze Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
